Bupivacaine liposomal hydrogel encapsulated - Virpax Pharmaceuticals/Lipocure
Alternative Names: Bupigel; Bupisome; LBL 100; LC-400; LMVV bupivacaine; Probudur™Latest Information Update: 15 Jul 2024
At a glance
- Originator LipoCure
- Developer LipoCure; Virpax Pharmaceuticals
- Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Postoperative pain
Most Recent Events
- 09 Jul 2024 Pharmacokinetics and adverse events data from preclinical trial in Postoperative pain released by Virpax
- 30 Apr 2024 Virpax Pharmaceuticals plans to file an IND application with the US FDA in USA for Postoperative pain
- 30 Apr 2024 Pharmacodynamics and adverse events data from preclinical trial in Postoperative pain released by Virpax